Moreover, the observed decreases in pRb and cell cycle progression, as monitored by levels of TopoIIα, were sustainable with continuous exposure of breast cancer cells (T-47D) to abemaciclib, with increased effects observed with longer initial treatment times of abemaciclib (Figure 2C). Here, RB1 is linked to breast cancer.